Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 76

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Structure/function of α‐synuclein in health and disease: rational development of animal models for Parkinson's and related diseases

Kahle, Philipp J., Haass, Christian, Kretzschmar, Hans A., Neumann, Manuela · 2002 · Journal of Neurochemistry

Abstract

α-Synuclein (αSYN) was originally identified in the electric organ of the electric eel Torpedo californica ( Maroteaux et al. 1988 ). It is now well documented that αSYN and its close homolog βSYN are abundantly expressed in presynaptic terminals of vertebrates. Experimental down-regulation of αSYN in knock-out mice and in primary neurones suggests that αSYN regulates synaptic neurotransmission, but the molecular mechanism is still poorly understood. A breakthrough was achieved when two different mutations in the αSYN gene were identified in autosomal-dominant hereditary Parkinson's disease (PD) patients. Soon thereafter, αSYN was found to be the major protein component in the hallmark lesions of PD [Lewy bodies (LBs) and Lewy neurites]. Lewy pathology is also characteristic for dementia with LBs (DLB), the LB variant of Alzheimer's disease, and neurodegeneration with brain iron accumulation type 1 (formerly known as Hallervorden–Spatz disease). Moreover, αSYN fibrils are deposited in (oligodendro)glial cytoplasmic inclusions (GCIs) of multiple system atrophy (MSA) patients. α-Synuclein specifically has an intrinsic propensity to form fibrils in vitro. PD-associated mutations and oxidative stress enhance αSYN aggregation. During fibril formation, the naturally unfolded αSYN undergoes conformational changes, transiently existing as a partially folded intermediate and protofibril. It is a matter of intense research to establish whether the folding intermediates and/or the LB fibrils exert neurotoxicity in human patients. To better understand the pathophysiology of αSYN, a number of transgenic animal models have been developed. Expression of human αSYN in Drosophila melanogaster caused age-dependent, dopamine-selective neurodegeneration and the formation of LB-like deposits. A variety of promoters have been used to express transgenic αSYN in mice. Aberrant accumulation of αSYN in cell bodies and swollen neurites were common observations. Some models displayed age-dependent enhancement of phenotype, such as formation of ubiquitin-positive inclusions, loss of dopaminergic synapses and locomotor deficits. Of great relevance are recent reports that amyloid seeded αSYN aggregation, whereas the non-amyloidogenic βSYN inhibited αSYN fibril formation both in vitro and in vivo. Still, additional genetic and/or environmental risk factors need to be considered in order to generate a complete mouse model of PD. The synucleins comprise a family of 15–20-kDa proteins including αSYN, βSYN and γSYN (also termed persyn) (Kahle et al. 2000a). The primary sequences span three regions (Fig. 1a). The amino-terminal half is characterized by five or six imperfectly conserved repeats (EKTKEGV, single-letter code). This region acquires α-helical secondary structure upon lipid binding (Eliezer et al. 2001), whereas the less conserved carboxy-terminus, in which acidic amino acid side chains are clustered, is highly flexible (Eliezer et al. 2001). A stretch of amino acids critically involved in αSYN aggregation (Giasson et al. 2001; Kahle et al. 2001) resides in the central, hydrophobic portion (called non-amyloid component [NAC]). (a) Schematic representation of synucleins. The imperfect KTKEGV repeats are numbered, the 6th repeat missing in βSYN is stippled. (b and c) Kyte–Doolittle hydropathy plots of αSYN (b) and βSYN (c). The NAC domain amino acid sequences are aligned in the middle, and are indicated by black boxes under each hydropathy plot. The natural deletion in βSYN is stippled. (dand e) Cortical LBs in the temporal cortex (arrows) in a DLB case showing strong αSYN immunoreactivity (d), but no labeling for βSYN (e). The absence of βSYN immunoreactivity in an LB (arrow) displacing a neuronal nucleus (arrowhead) is featured in the insert. The amino-terminal repeats of αSYN were predicted to form an α-helical structure similar to the lipid-binding domains of class A2 apolipoproteins (Davidson et al. 1998). Indeed, αSYN tightly binds to synthetic phospholipid vesicles, and preferentially binds to those with acidic head groups (Davidson et al. 1998; Jo et al. 2000). Mutational analysis of lipid-binding determinants (Perrin et al. 2000) revealed that the lipid-binding domain was broadly distributed over the amino-terminal half of αSYN. Amphipathic class A2 helix formation was crucial because replacement of the six amino-terminal threonines (predicted to lie along the hydrophobic face of the helix) with charged amino acids disrupted binding of mutant αSYN with vesicles. Recombinant full-length, but not amino-terminally truncated αSYN interacted with a crude membrane fraction from rat brain (Jensen et al. 1998). Both PD-associated mutations (A53T, Polymeropoulos et al. 1997; A30P, Krüger et al. 1998) reside in the lipid-binding amino-terminus of αSYN (Fig. 1a). The A30P mutation abolishes a helical moment in the amino-terminus (Bussell and Eliezer 2001), and was reported to disrupt αSYN binding to rat brain membranes (Jensen et al. 19

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1471-4159.2002.01020.x

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 84

  1. 10.1016/S0304-3940(00)01049-1 · DOI
  2. 10.1016/S0304-3940(00)01623-2 · DOI
  3. 10.1212/WNL.51.3.887 · DOI · Paper page
  4. Baba M., 1998, Aggregation of α‐synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies, Am. J. Pathol., 152, 879
  5. 10.1016/S0304-3940(99)00311-0 · DOI
  6. 10.1126/science.292.5521.1552 · DOI · Paper page
  7. 10.1038/81834 · DOI · Paper page
  8. 10.1074/jbc.M106777200 · DOI · Paper page
  9. CampbellB. C. LiQ.‐X. CulvenorJ. G. JäkäläP. CappaiR. BeyreutherK. MastersC. L.andMcLeanC. A.(2000) Accumulation of insoluble α‐synuclein in dementia with Lewy bodies.Neurobiol. Dis.7 192–200. · DOI
  10. 10.1038/3311 · DOI · Paper page
  11. 10.1021/bi991447r · DOI · Paper page
  12. 10.1073/pnas.97.2.571 · DOI · Paper page
  13. 10.1126/science.1063522 · DOI · Paper page
  14. 10.1016/S0002-9440(10)65220-0 · DOI · Paper page
  15. 10.1074/jbc.273.16.9443 · DOI · Paper page
  16. 10.1006/jmbi.2001.4538 · DOI · Paper page
  17. 10.1038/35006074 · DOI · Paper page
  18. Fujiwara H., 2002, α‐Synuclein is phosphorylated in synucleinopathy lesions, Nat. Cell. Biol, 4, 160–164, 10.1038/ncb748 · DOI · Paper page
  19. 10.1016/S0140-6736(05)79256-4 · DOI · Paper page
  20. 10.1016/S0002-9440(10)64548-8 · DOI · Paper page
  21. 10.1016/0896-6273(95)90040-3 · DOI · Paper page
  22. 10.1007/BF01291788 · DOI · Paper page
  23. 10.1046/j.1471-4159.2000.0752221.x · DOI
  24. 10.1074/jbc.274.12.7619 · DOI · Paper page
  25. 10.1126/science.290.5493.985 · DOI · Paper page
  26. 10.1016/S0896-6273(02)00682-7 · DOI · Paper page
  27. 10.1016/S0959-437X(00)00200-8 · DOI
  28. 10.1016/S0006-8993(98)00514-9 · DOI · Paper page
  29. 10.1097/00001756-199903170-00011 · DOI · Paper page
  30. 10.1074/jbc.274.41.28849 · DOI · Paper page
  31. 10.1146/annurev.biochem.67.1.425 · DOI · Paper page
  32. 10.1212/WNL.54.10.1916 · DOI · Paper page
  33. 10.1083/jcb.96.5.1374 · DOI · Paper page
  34. 10.1097/00005072-199804000-00005 · DOI · Paper page
  35. 10.1074/jbc.273.41.26292 · DOI · Paper page
  36. 10.1074/jbc.M004345200 · DOI · Paper page
  37. 10.1111/j.1749-6632.2000.tb06902.x · DOI
  38. 10.1523/JNEUROSCI.20-17-06365.2000 · DOI · Paper page
  39. 10.1016/S0002-9440(10)63072-6 · DOI · Paper page
  40. 10.1212/WNL.56.7.980 · DOI
  41. 10.1021/bi001441y · DOI
  42. 10.1097/00001756-200001170-00041 · DOI · Paper page
  43. 10.1038/ng0298-106 · DOI · Paper page
  44. 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F · DOI
  45. 10.1096/fsb2fj000334com · doi:10.1096/fsb2fj000334com · Paper page
  46. 10.1074/jbc.M105326200 · DOI · Paper page
  47. 10.1021/bi010616g · DOI · Paper page
  48. 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4 · doi:10.1002/1531-8249(199903)45:3<353::aid-ana11>3.0.co;2-4
  49. 10.1523/JNEUROSCI.08-08-02804.1988 · DOI · Paper page
  50. 10.1126/science.287.5456.1265 · DOI · Paper page
  51. 10.1007/s004019900168 · DOI · Paper page
  52. 10.1074/jbc.275.12.8812 · DOI · Paper page
  53. 10.1523/JNEUROSCI.20-09-03214.2000 · DOI · Paper page
  54. 10.1111/j.1432-1033.1993.tb18337.x · DOI · Paper page
  55. 10.1021/bi002952n · DOI · Paper page
  56. 10.1074/jbc.274.14.9843 · DOI · Paper page
  57. 10.1074/jbc.275.1.390 · DOI · Paper page
  58. 10.1074/jbc.M004851200 · DOI · Paper page
  59. 10.1126/science.276.5321.2045 · DOI · Paper page
  60. 10.1074/jbc.M003542200 · DOI · Paper page
  61. 10.1523/JNEUROSCI.20-16-06021.2000 · DOI · Paper page
  62. 10.1046/j.1471-4159.2001.00474.x · DOI · Paper page
  63. 10.1016/S0006-8993(01)02772-X · DOI · Paper page
  64. 10.1073/pnas.97.9.4897 · DOI · Paper page
  65. Sharma N., 2001, Alpha‐synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies, Acta Neuropathol., 102, 329, 10.1007/s004010100369 · DOI
  66. 10.1016/0006-8993(93)90796-P · DOI
  67. 10.1074/jbc.M000206200 · DOI · Paper page
  68. 10.1016/S0304-3940(98)00504-7 · DOI · Paper page
  69. 10.1073/pnas.95.11.6469 · DOI · Paper page
  70. 10.1038/42166 · DOI · Paper page
  71. Takeda A., 1998, Abnormal accumulation of NACP/α‐synuclein in neurodegenerative disorders, Am. J. Pathol., 152, 367
  72. 10.1016/S0014-5793(01)03115-5 · DOI · Paper page
  73. 10.1073/pnas.90.23.11282 · DOI · Paper page
  74. 10.1074/jbc.M105343200 · DOI · Paper page
  75. 10.1016/S0014-5793(01)02597-2 · DOI · Paper page
  76. 10.1046/j.1471-4159.2000.740721.x · DOI · Paper page
  77. 10.1021/bi0102398 · DOI · Paper page
  78. 10.1016/S0304-3940(97)00891-4 · DOI · Paper page
  79. 10.1046/j.1365-2990.1999.00193.x · DOI
  80. 10.1021/bi961799n · DOI · Paper page
  81. 10.1097/00001756-200011270-00029 · DOI
  82. 10.1016/S0165-3806(96)00210-6 · DOI · Paper page
  83. 10.1074/jbc.274.28.19509 · DOI · Paper page
  84. 10.1016/S0006-8993(99)02207-6 · DOI

Cited by

See all 76

Metadata

Authors
Kahle, P. J., Haass, C., Kretzschmar, H. A., & Neumann, M.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2002-07-24
Volume
82
Issue
3
Pages
449-457
ISSN
  • 0022-3042
  • 1471-4159
Cited by
76
References
16
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structure/function of α‐synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. https://app.cochat.ai/papers/10.1046/j.1471-4159.2002.01020.x
The paper
Kahle, P. J., Haass, C., Kretzschmar, H. A., & Neumann, M. (2002). Structure/function of α‐synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. Journal of Neurochemistry. https://doi.org/10.1046/j.1471-4159.2002.01020.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.